AR060604A1 - Nuevos arilamino n- heteroarilos como inhibidores de mek - Google Patents

Nuevos arilamino n- heteroarilos como inhibidores de mek

Info

Publication number
AR060604A1
AR060604A1 ARP070101676A ARP070101676A AR060604A1 AR 060604 A1 AR060604 A1 AR 060604A1 AR P070101676 A ARP070101676 A AR P070101676A AR P070101676 A ARP070101676 A AR P070101676A AR 060604 A1 AR060604 A1 AR 060604A1
Authority
AR
Argentina
Prior art keywords
alkyl
heterocycloalkyl
aryl
nr7r8
heteroaryl
Prior art date
Application number
ARP070101676A
Other languages
English (en)
Inventor
Benny C Askew Jr
Kiet Diep Nhut
Andreas Goutopoulos
Srinivasa Karra
Henry Yu
Matthias Schwarz
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of AR060604A1 publication Critical patent/AR060604A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Dichos compuestos son inhibidores de MEK que son utiles en el tratamiento de enfermedades hiperproliferativas, tales como cáncer e inflamacion. Se describe también el tratamiento de una enfermedad hiperproliferativa en mamíferos, y composiciones farmacéuticas que contienen dichos compuestos. Reivindicacion 1: Un compuesto de formula (1), así como tautomeros, sales farmacéuticamente aceptables y derivados farmacéuticamente activos del mismo, en la que: Het se selecciona entre las formulas (2) en la que * es la posicion de conexion; W se selecciona entre: 1) heteroarilo que contiene 1-4 heteroátomos o heterocicloalquilo que contiene 1-4 heteroátomos, estando cada uno de los cuales opcionalmente sustituido con 1 a 5 sustituyentes R11; y 2) es arilo, halogeno, alquilo C1-10-OR6, alquilo C1-10-NR7R8, -C=NNR6R7, -O=NOR7, alquilo C1-10(NR7)(NR7R8), -C(O)R6, -C(O)OR6, -C(O)NR7R8, -C(O)NR7OR6, -C(O)(cicloalquilo C3-10), -C(O)(alquilo C1-10), -C(O)(arilo), -C(O)NR7(alquil C1- 10)heterocicloalquilo, -C(O)(heteroarilo), -C(O)(heterocicloalquilo), -CN, -C(O)NR7NR8R6, -C(O)C(O)R6, -C(O)CR6R7C(O)R8, -NR7R8, -NR7C(O)R8, -NRC(O)NR7R8, o -C(O)NR7NR8C(O)R6; R1 y R9 se seleccionan independientemente entre hidrogeno, halogeno, ciano, azido, alquilo C1-6, alcoxi C1-6, cicloalquilo C3-10 , arilo, heteroarilo, heterocicloalquilo, alquilo C1-4-C(O)OR6, alquilo C1-4-OR6, alquilo C1-4-C(O)NR7R6, -C(O)OR6, -C(O)R6, -NR7C(O)OR6, -OC(O)R6, -NR7R8, -SR6 y -NR7S(O)2R6, donde dicho alquilo, arilo, heteroarilo y heterocicloalquilo están sustituidos o no sustituidos; R2 y R3 son independientemente halogeno; R4 y R5 se seleccionan independientemente entre hidrogeno, halogeno, alquilo C1-6 y alcoxi C1-6, donde dicho alquilo o alcoxi está sustituido o no sustituido; R6, R7 y R8 se seleccionan independientemente entre hidrogeno, alquilo C1-10, cicloalquilo C3-10, arilo, arilalquilo, heteroarilo, o heterocicloalquilo, alquilo C1-4-C(O)OR', alquilo C1-4-OR', alquilo C1-4- (heterocicloalquilo), alquilo C1-4-diol, y alquilo C1-4-C(O)NR'Rö, donde dicho alquilo, cicloalquilo, arilo, heteroarilo y heterocicloalquilo están sustituidos o no sustituidos; o R7 y R8 pueden tomarse junto con el átomo al que están unidos para formar un anillo de heteroarilo o heterocicloalquilo de 4 a 10 miembros, con 1-4 heteroátomos, estando cada uno de los cuales sustituido o no sustituido; R10 se selecciona entre hidrogeno, halogeno y alquilo C1-6; donde dicho alquilo está sustituido o no sustituido; R11 se selecciona entre: hidrogeno, alquilo C1-6, -OR6, -NR7R8, -SR6 y NR7S(O)2R'; y R' y Rö se seleccionan independientemente entre hidrogeno, alquilo C1-6 o arilo, donde dicho alquilo o arilo está sustituido o no sustituido.
ARP070101676A 2006-04-19 2007-04-19 Nuevos arilamino n- heteroarilos como inhibidores de mek AR060604A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79307206P 2006-04-19 2006-04-19

Publications (1)

Publication Number Publication Date
AR060604A1 true AR060604A1 (es) 2008-07-02

Family

ID=38308695

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101676A AR060604A1 (es) 2006-04-19 2007-04-19 Nuevos arilamino n- heteroarilos como inhibidores de mek

Country Status (3)

Country Link
US (2) US7772233B2 (es)
AR (1) AR060604A1 (es)
WO (1) WO2007123939A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5670325B2 (ja) * 2008-06-19 2015-02-18 エックスカバリー ホールディング カンパニー エルエルシー キナーゼ阻害化合物としての置換されたピリダジンカルボキサミド化合物
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
ES2576061T3 (es) 2010-02-25 2016-07-05 Dana-Farber Cancer Institute, Inc. Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF
BR112012022801B8 (pt) 2010-03-09 2019-10-29 Dana Farber Cancer Inst Inc método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
WO2012100135A1 (en) * 2011-01-21 2012-07-26 Abbott Laboratories Picolinamide inhibitors of kinases
US9029553B2 (en) 2011-02-14 2015-05-12 Council Of Scientific & Industrial Research 2-anilino nicotinyl linked 2-amino benzothiazole conjugates and process for the preparation thereof
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
US10379046B2 (en) * 2015-04-08 2019-08-13 Molecular Devices, Llc Method and system for multiplexed time-resolved fluorescence detection
US11971354B2 (en) 2015-04-08 2024-04-30 Molecular Devices, Llc Methods and systems for fluorescence detection using infrared dyes
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
WO2020106305A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Thienyl-aniline compounds for treatment of dermal disorders
WO2020106306A1 (en) * 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
WO2020106308A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
CA3120351A1 (en) * 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
US12280055B2 (en) 2021-05-27 2025-04-22 Mirati Therapeutics, Inc. Combination therapies
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE422799B (sv) 1975-05-28 1982-03-29 Merck & Co Inc Analogiforfarande for framstellning av 1,3-dihydroimidazo (4,5-b)pyridin-2-oner
DD204480A1 (de) 1982-04-13 1983-11-30 Meisel Verfahren zur herstellung von in 10-stellung basisch substituierten 5,5-dimethyl-5,10-dihydro-benzo(b)(1,8)naphthyridinen
AT392789B (de) 1985-01-23 1991-06-10 Toyama Chemical Co Ltd Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten
NZ218773A (en) 1986-01-06 1990-05-28 Carpibem 3-methyl-2-oxo-1-(substituted phenyl)-naphthyridines and pharmaceutical compositions
US4740511A (en) 1987-02-18 1988-04-26 Schering Corporation Method of treating hyperproliferative skin disease
US6956047B1 (en) 1995-06-06 2005-10-18 Pfizer Inc. Corticotropin releasing factor antagonists
JPH11292720A (ja) * 1998-04-13 1999-10-26 Nissan Chem Ind Ltd 縮合イミダゾリノン誘導体を含有する除草剤
DE69926914T2 (de) 1999-01-13 2006-06-29 Warner-Lambert Co. Llc 1-heterozyklus-substituierte diarylaminen
US6664256B1 (en) * 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same
AU2003293376A1 (en) * 2002-12-10 2004-06-30 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
US20050004186A1 (en) * 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
CN1905873A (zh) 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
ZA200703912B (en) 2004-10-20 2008-09-25 Serono Lab 3-arylamino pyridine derivatives
EA200802050A1 (ru) 2006-04-19 2009-04-28 Лаборатуар Сероно Са Новые гетероарилзамещенные ариламинопиридиновые производные в качестве мек ингибиторов

Also Published As

Publication number Publication date
WO2007123939A8 (en) 2008-03-13
WO2007123939A2 (en) 2007-11-01
US7772233B2 (en) 2010-08-10
WO2007123939A3 (en) 2007-12-21
US20100256149A1 (en) 2010-10-07
US8802703B2 (en) 2014-08-12
US20070287709A1 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
AR060604A1 (es) Nuevos arilamino n- heteroarilos como inhibidores de mek
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR066509A1 (es) Derivados de tiazol, medicamentos que los contienen, proceso de preparacion y usos como moduladores de beta amiloide.
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
AR075583A1 (es) Derivados de isoxazol/o-piridina con eslabon etilo o etenilo
PE20120058A1 (es) Derivados de imidazopirazina como inhibidores de syk
PE20160240A1 (es) Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR056691A1 (es) Derivados pirrolopirimidina como inhibidores de syk
AR077977A1 (es) Compuestos y composiciones como inhibidores de cinasa de proteina
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PE20090904A1 (es) ARILOXAZOLES SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE ADENOSINA A1 Y/O A2b
AR083058A1 (es) Compuestos de estructura de imidazotriazinona
MX2015015893A (es) 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen.
AR083542A1 (es) Piperidin-4-il-azetidin diamidas como inhibidores de monoacilglicerol lipasa
PE20091095A1 (es) Moduladores de gamma secretasa
AR073314A1 (es) Derivados de indazol o de 4,5,6,7-tetrahidro-indazol
AR051485A1 (es) Pirazolo pirimidinas 1,4-sustituidas como inhibidores de quinasa
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
AR068846A1 (es) Compuestos derivados de pirrolo (2,3d)-pirimidina inhibidores de la actividad de pkb, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como agentes anticancer
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
AR072962A1 (es) Derivados de pirimidin-4-ona sustituidos
JP2013509392A5 (es)
AR061603A1 (es) Derivados de etenilcarboxamidas microbicidas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal